{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T19:41:48Z","timestamp":1775504508082,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270177"],"award-info":[{"award-number":["82270177"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270177"],"award-info":[{"award-number":["82270177"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research Fund of Tongji Hospital","award":["2024TJCR022"],"award-info":[{"award-number":["2024TJCR022"]}]},{"name":"Research Fund of Tongji Hospital","award":["2024TJCR022"],"award-info":[{"award-number":["2024TJCR022"]}]},{"name":"Natural Scinence Foundation of Hubei Province","award":["2024AFD422"],"award-info":[{"award-number":["2024AFD422"]}]},{"name":"Beijing Xisike Clinical Oncology Study Foundation","award":["Y-SYBLD2022MS-0062"],"award-info":[{"award-number":["Y-SYBLD2022MS-0062"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s00277-025-06551-3","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T05:17:59Z","timestamp":1756099079000},"page":"4539-4547","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical outcomes with high dose cytarabine and idarubicin consolidation for adult AML patients"],"prefix":"10.1007","volume":"104","author":[{"given":"Bingxin","family":"Qian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guiqin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoya","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dengju","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"issue":"10393","key":"6551_CR1","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo CD, Erba HP, Freeman SD, Wei AH (2023) Acute myeloid leukaemia. The Lancet 401(10393):2073\u20132086. https:\/\/doi.org\/10.1016\/S0140-6736(23)00108-3","journal-title":"The Lancet"},{"issue":"9","key":"6551_CR2","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.3324\/haematol.2022.281810","volume":"108","author":"J Senapati","year":"2023","unstructured":"Senapati J, Kadia TM, Ravandi F (2023) Maintenance therapy in acute myeloid leukemia: advances and controversies. Haematologica 108(9):2289\u20132304. https:\/\/doi.org\/10.3324\/haematol.2022.281810","journal-title":"Haematologica"},{"issue":"10","key":"6551_CR3","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.3324\/haematol.2020.269134","volume":"106","author":"SR McCurdy","year":"2021","unstructured":"McCurdy SR, Luger SM (2021) Dose intensity for induction in acute myeloid leukemia: what, when, and for whom? Haematologica 106(10):2544\u20132554. https:\/\/doi.org\/10.3324\/haematol.2020.269134","journal-title":"Haematologica"},{"issue":"7","key":"6551_CR4","doi-asserted-by":"publisher","first-page":"e441","DOI":"10.1038\/bcj.2016.50","volume":"6","author":"I De Kouchkovsky","year":"2016","unstructured":"De Kouchkovsky I, Abdul-Hay M (2016) acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J 6(7):e441\u2013e441. https:\/\/doi.org\/10.1038\/bcj.2016.50","journal-title":"Blood Cancer J"},{"issue":"8","key":"6551_CR5","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1182\/blood-2010-07-295279","volume":"117","author":"S Miyawaki","year":"2011","unstructured":"Miyawaki S, Ohtake S, Fujisawa S et al (2011) A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood 117(8):2366\u20132372. https:\/\/doi.org\/10.1182\/blood-2010-07-295279","journal-title":"Blood"},{"key":"6551_CR6","unstructured":"Pollyea DA, Altman JK, Assi R, Bachiashvili K, Fathi AT, Foran JM. NCCN Clinical Practice Guidelines in Oncology: acute myeloid leukemia, version 3.2024. NCCN. May 17, 2024. Accessed 19 Nov 2024. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1411"},{"issue":"1","key":"6551_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2012-07-444851","volume":"121","author":"B L\u00f6wenberg","year":"2013","unstructured":"L\u00f6wenberg B (2013) Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood 121(1):26\u201328. https:\/\/doi.org\/10.1182\/blood-2012-07-444851","journal-title":"Blood"},{"issue":"26","key":"6551_CR8","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ et al (2021) 2021 update on MRD in acute myeloid leukemia: a consensus document from the european LeukemiaNet MRD working party. Blood 138(26):2753\u20132767. https:\/\/doi.org\/10.1182\/blood.2021013626","journal-title":"Blood"},{"issue":"12","key":"6551_CR9","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867","journal-title":"Blood"},{"issue":"1","key":"6551_CR10","doi-asserted-by":"publisher","first-page":"16010","DOI":"10.1038\/nrdp.2016.10","volume":"2","author":"A Khwaja","year":"2016","unstructured":"Khwaja A, Bjorkholm M, Gale RE et al (2016) Acute myeloid leukaemia. Nat Rev Dis Primer 2(1):16010. https:\/\/doi.org\/10.1038\/nrdp.2016.10","journal-title":"Nat Rev Dis Primer"},{"issue":"12","key":"6551_CR11","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1182\/blood.V90.12.4719","volume":"90","author":"M de Lima","year":"1997","unstructured":"de Lima M, Strom SS, Keating M et al (1997) Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work. Blood 90(12):4719\u20134724","journal-title":"Blood"},{"issue":"11","key":"6551_CR12","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.3324\/haematol.2014.114611","volume":"99","author":"RF Schlenk","year":"2014","unstructured":"Schlenk RF (2014) Post-remission therapy for acute myeloid leukemia. Haematologica 99(11):1663\u20131670. https:\/\/doi.org\/10.3324\/haematol.2014.114611","journal-title":"Haematologica"},{"issue":"14","key":"6551_CR13","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJM199410063311402","volume":"331","author":"Robert J Mayer","year":"1994","unstructured":"Mayer Robert J, Davis Roger B, Schiffer Charles A et al (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 331(14):896\u2013903. https:\/\/doi.org\/10.1056\/NEJM199410063311402","journal-title":"N Engl J Med"},{"key":"6551_CR14","doi-asserted-by":"crossref","unstructured":"Jk W, Kj K, Fr A, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1996;88(8). Accessed 18 Nov 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/8874180\/","DOI":"10.1182\/blood.V88.8.2841.bloodjournal8882841"},{"key":"6551_CR15","doi-asserted-by":"crossref","unstructured":"Jf B, Jp M, Ga Y, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 1996;87(5). Accessed 18 Nov 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/8634416\/","DOI":"10.1182\/blood.V87.5.1710.bloodjournal8751710"},{"issue":"11","key":"6551_CR16","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1056\/NEJMoa1010222","volume":"364","author":"L\u00f6wenberg Bob","year":"2011","unstructured":"Bob L\u00f6wenberg, Thomas Pabst, Edo Vellenga et al (2011) Cytarabine dose for acute myeloid leukemia. N Engl J Med 364(11):1027\u20131036. https:\/\/doi.org\/10.1056\/NEJMoa1010222","journal-title":"N Engl J Med"},{"issue":"19","key":"6551_CR17","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1200\/JCO.2010.33.7303","volume":"29","author":"M Schaich","year":"2011","unstructured":"Schaich M, R\u00f6llig C, Soucek S et al (2011) Cytarabine Dose of 36 g\/m2 Compared With 12 g\/m2 Within First Consolidation in Acute Myeloid Leukemia: Results of Patients Enrolled Onto the Prospective Randomized AML96 Study. J Clin Oncol 29(19):2696\u20132702. https:\/\/doi.org\/10.1200\/JCO.2010.33.7303","journal-title":"J Clin Oncol"},{"issue":"8","key":"6551_CR18","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1182\/blood.V77.8.1666.1666","volume":"77","author":"E Berman","year":"1991","unstructured":"Berman E, Heller G, Santorsa J et al (1991) Results of a Randomized Trial Comparing Idarubicin and Cytosine Arabinoside With Daunorubicin and Cytosine Arabinoside in Adult Patients With Newly Diagnosed Acute Myelogenous Leukemia. Blood 77(8):1666\u20131674. https:\/\/doi.org\/10.1182\/blood.V77.8.1666.1666","journal-title":"Blood"},{"issue":"7","key":"6551_CR19","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1200\/JCO.1992.10.7.1103","volume":"10","author":"WR Vogler","year":"1992","unstructured":"Vogler WR, Velez-Garcia E, Weiner RS et al (1992) A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol Off J Am Soc Clin Oncol 10(7):1103\u20131111. https:\/\/doi.org\/10.1200\/JCO.1992.10.7.1103","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"6551_CR20","doi-asserted-by":"crossref","unstructured":"Ph W, Pl B, Dc C, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992;79(2). Accessed 19 Nov 2024. https:\/\/pubmed.ncbi.nlm.nih.gov\/1730080\/","DOI":"10.1182\/blood.V79.2.313.bloodjournal792313"},{"issue":"6","key":"6551_CR21","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jamaoncol.2018.6634","volume":"5","author":"EAM Feijen","year":"2019","unstructured":"Feijen EAM, Leisenring WM, Stratton KL et al (2019) Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity. JAMA Oncol 5(6):864. https:\/\/doi.org\/10.1001\/jamaoncol.2018.6634","journal-title":"JAMA Oncol"},{"issue":"11","key":"6551_CR22","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/ajh.23834","volume":"89","author":"EH Estey","year":"2014","unstructured":"Estey EH (2014) Acute myeloid leukemia: 2014 Update on risk-stratification and management. Am J Hematol 89(11):1063\u20131081. https:\/\/doi.org\/10.1002\/ajh.23834","journal-title":"Am J Hematol"},{"issue":"7","key":"6551_CR23","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1200\/JCO.1985.3.7.992","volume":"3","author":"RH Herzig","year":"1985","unstructured":"Herzig RH, Lazarus HM, Wolff SN, Phillips GL, Herzig GP (1985) High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. J Clin Oncol Off J Am Soc Clin Oncol 3(7):992\u2013997. https:\/\/doi.org\/10.1200\/JCO.1985.3.7.992","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"6551_CR24","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s00277-023-05087-8","volume":"102","author":"D Niederwieser","year":"2023","unstructured":"Niederwieser D, Lang T, Krahl R et al (2023) Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized german inter-group study. Ann Hematol 102(3):547\u2013561. https:\/\/doi.org\/10.1007\/s00277-023-05087-8","journal-title":"Ann Hematol"},{"issue":"8","key":"6551_CR25","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1182\/blood-2010-03-273243","volume":"117","author":"S Ohtake","year":"2011","unstructured":"Ohtake S, Miyawaki S, Fujita H et al (2011) Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood 117(8):2358\u20132365. https:\/\/doi.org\/10.1182\/blood-2010-03-273243","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06551-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06551-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06551-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:30:23Z","timestamp":1761283823000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06551-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["6551"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06551-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study design was approved by the Medical Ethics Committee of Tongji hospital and conducted in adherence to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"No materials from other sources were used in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Permission to reproduce material from other sources"}},{"value":"The need for informed consent was waived owing to the retrospective nature of the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent statement"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare that they have no conflicts of interest related to this study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest disclosure"}}]}}